MamaLift Plus
Commercial- Indications
- Postpartum depression
Company intelligence / Profile preview
Curio’s pivotal randomized controlled trial for MamaLift Plus met primary and key secondary efficacy endpoints for the treatment of postpartum depression. The product is FDA-cleared as the first prescription digital therapeutic for PPD. Seven clinical studies have been published supporting its effectiveness, with evidence of significant improvement in depressive symptoms measured by EPDS scores.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Curio Digital Therapeutics.